See the DrugPatentWatch profile for lurbinectedin

Based on the information provided, there is no explicit mention of adverse effects in breastfeeding mothers taking lurbinectedin. Lurbinectedin is an antineoplastic agent, used to treat metastatic small cell lung cancer, and its effects on pregnant or breastfeeding women have not been extensively studied [1].

However, it is generally recommended that women avoid taking medication while breastfeeding, unless the potential benefits outweigh the risks [2]. The U.S. National Library of Medicine states that "it is not known whether lurbinectedin is excreted in human milk" [3]. This lack of knowledge indicates a potential risk, as drugs in breast milk can affect a nursing infant's health [2].

In conclusion, while there are no reported adverse effects of lurbinectedin in breastfeeding mothers, it is generally advisable to avoid taking this medication while breastfeeding due to potential risks and the lack of sufficient research. Always consult with a healthcare provider before making decisions regarding medication use during breastfeeding.

Sources:
[1] DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/drugs/lurbinectedin
[2] U.S. National Library of Medicine. (2021, May 11). Breastfeeding and medication. MedlinePlus. Retrieved from https://medlineplus.gov/ency/article/002469.htm
[3] U.S. National Library of Medicine. (2021, May 11). Lurbinectedin. DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5e1a111e-6e3f-4e1e-9a31-8a5e35a21a5a&type=display